“Hey, did you hear?”
“No interest rate hike this month.”
And so the market is once again left alone to roam around the vast horizon to go where it has never gone before…
That is a very nice green weekly bar to bounce back above the short 5 MA line. It is cleared for take off from here.
With the phantom hand that held the leg of the market vanished, my port also becomes active all on its own. Basically, I don’t have to do anything anymore. No buying and selling on my part. Everyone of them is pretty much a buy and hold. So the only thing left for me to do is to monitor the fundamental developments. So far so good. Let me show you…
Let’s start with $DMRC
$DMRC has quite a volatile week since it dipped at the start of the week and then ended the week higher.
What transpired at the daily (above) and weekly (below) $DMRC charts are further proof of the magical quality of the 79 & 89 MA supports line. From the daily chart above, notice how price bounced off the 79 & 89 support lines three times. 1st time in June 28; 2nd in August 5th, and 3rd time in September 20th, Tuesday of this week.
From the weekly chart above, price bounced off the 79 & 89 MA weekly support lines on the week ended August 5th which happened to coincide with the daily 79 & 89 MA lines as well. The weekly chart also showed that price is now bouncing off this week 15 MA support.
Basically, the 79 & 89 MA support lines on both the daily & weekly charts are telling me that $DMRC is ready to bounce higher from here.
Fundamentally speaking, Digimarc expands its foothold in the international arena by the following announcement on Wednesday:
GS1 Germany and Digimarc Announce Collaboration to Bring DWCode to the German Market
BEAVERTON, Ore. and COLOGNE, Germany, Sept. 21, 2016 /PRNewswire/ — Digimarc Corporation (DMRC) and GS1 Germany today announced at ECR Tag in Berlin their joint effort to speed the industry adoption of DWCode by GS1 Germany customers e.g. manufacturer and retailer. DWCode was developed in a collaboration between Digimarc and GS1 US and launched in June 2016. The pioneering imperceptible barcode technology delivers many benefits like faster check out, more efficient store operations to retailers, and easy provision of brand information to consumers by scanning packages with smartphones.
This announcement followed from the recent “Shopping for The Future” Group Formed in Japan to study Digimarc® Barcode Impact. In a nutshell, the Digimarc barcode, while simmering in the U.S. territory, is already laying groundwork outside the U.S. If you take a moment to think about this, when the time comes that Digimarc barcode is going to be imminently adopted by the retail world, it won’t be just the U.S. alone, it would be a global adoption right off the bat. This is the main reason why I believe this is a buy and hold due to the simple possibility that this could be the next Priceline, Netflix, etc in the making. This $30ish price is akin to $TSLA and $PCLN trading at the $30ish level before taking off to make their historical climbs.
Sometimes in the future, we are going to look back and wondered why we didn’t buy more..
$SEED also bounced nicely to close the week.
When you look at the weekly chart above, there is only one trend happening and it is to the upside. Come on now, China is opening its door to GMO seeds and the streets are still not connecting the dots yet. Wait until the dots get connected and we are going to have an exciting show to watch. Meanwhile, I’ll do my best to hold on to my shares and ride this one out.
Next is $AKER
$AKER also suffered a volatile week but recovered nicely.
Chart continues to look bullish despite the recent dip. With the 3rd quarter coming to its conclusion, the revenues surprise will be the one major catalyst to pop this one up big time. I’m betting that their BreathScan OxiCheck disposable breath test is going to be a big seller. If this is the case, then Akers Biosciences has nowhere else to go but up and up.
As of now, I’ve an earning update to look forward to. Holding long and strong.
$CARA is now roaring upward.
This week kicked off the uptrend with a breakout that is also at the cusp of breaking out of the downtrend line.
The current biotech market development could not have been better for Cara Therapeutics. The big news is that Allergen announced that they have entered into a definitive agreement under which Allergan will acquire Tobira for an upfront payment of $28.35 per share, in cash, and up to $49.84 per share in Contingent Value Rights (CVRs) that may be payable based on the successful completion of certain development, regulatory and commercial milestones, for a total potential consideration of up to $1.695 billion. The Boards of Directors of both companies have unanimously approved the transaction.
Tobira was a $4.74 stock and overnight it is now a $39.xx stock. Big Pharmaceutical companies are hungry and they are looking for new way to grow revenues. What’s better way than to buy something that has the potential to change the painkiller landscape?
Are there discussion going on that we don’t know about? No one saw the $TBRA acquisition coming and the chart did not provide clue as to what was coming either. So, to make sure I’m not missing any surprise, I’m not going to trade this stock. I’m going to ride thru the volatility to see what possibilities are out there in the making.
My 2 cents is that the current price of $CARA is ridiculously low giving its potential to change the painkiller market for the better. However, I also believe that the streets is finally waking up and is now connecting the dots. I expect to see more upside price momentum until we see teen.
$IBIO, while not doing much, was able to hold the fort at $0.55+.
There is not much to say here except to watch Dr. Carol A. Feghali-Bostwick, Ph.D’s recent presentation in the video below:
Go to 37:08 on the video, and you will hear “…we are getting close to Phase One clinical trial on humans…”
That is what I’m patiently waiting for. Everything else doesn’t matter. The price doesn’t matter; not now at least. And once the Phase One trial begins, any good news that it doesn’t harm the patients and we are going to see one mother-of-all rally here.
“Why? Phase Two hasn’t even begun yet if they passed Phase One…”
Here is my 2 cents, once IBIO-CFB03 proves to be safe, the odd of its success is very high due to the fact that Dr. Carol A. Feghali-Bostwick’s experimental result on human skin was positive. As presented in the video above, the human skin was “kept alive” with the necessary supporting nutrients. The transformation of the “human skin” under the treatment of IBIO-CFB03 is simply a tell-tale sign that it might work on a live human beings. This is my bet and this is why I’m very confident in holding my shares despite price volatility.
With three up, one even, and one down, my port did well this week to gain back prior weeks giveback.
Main port (no margin): DMRC SEED AKER CARA IBIO and 3% cash. (up 44% YTD)
Trading port (with margin): IBIO down 16% & $MENXF down 10% on positions only and up YTD on port. I also added to $MENXF when price drop below 25 cents.
My 2 cents
From my camera: